FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase ...

Nearly 3 in 4 adults undergoing metabolic bariatric surgery (MBS) at 4 international centers met criteria for clinical ...

Limited access to care means safety-net ICUs see advanced disease and poorer outcomes, while bias and social media add new ...

Pulmonologists play a key role in comprehensive biomarker testing, helping more patients with lung cancer access precise ...

Ryzumvi (phentolamine 0.75%) is FDA approved for presbyopia, its second indication after pharmacologically induced mydriasis.

The AAO 2026 annual meeting, held in New Orleans, Louisiana, from October 10 to October 12, 2026, was a weekend that provided ...

The National Community Oncology Dispensing Association, Inc. (NCODA) is a grassroots, not-for-profit organization, founded to strengthen oncology organizations with medically integrated dispensing ...

Intensive blood pressure (BP) lowering reduced the risk of major cardiovascular events by 15% for every 10-mm Hg reduction in ...

OneOncology's Larry Bilbrey explains how to guide practices on AI without endorsing products and why technology gaps outweigh ...

The FDA approved satralizumab-mwge (Enspryng; Genentech) on October 15, 2026, for adults with thyroid eye disease (TED) ...

Recent ENDURANCE data support 2-year lenalidomide maintenance in standard-risk multiple myeloma and individualize when to stop.

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...